Stocktoria
Summit Therapeutics Inc. SMMT
Summit Therapeutics Inc. (SMMT) earns a Piotroski F-score of 1/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-12 | Leerink Partners | Market Perform (up) |
| 2026-07-24 | Stifel | Buy (main) |
| 2026-07-24 | Guggenheim | Buy (main) |
| 2026-07-23 | HC Wainwright & Co. | Neutral (reit) |
| 2026-05-22 | Bernstein | Underperform (init) |
| 2026-05-22 | HC Wainwright & Co. | Neutral (down) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | 1/9 | — | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
FAQ
Is SMMT financially healthy?
Summit Therapeutics Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak).
Does SMMT pay a dividend?
No, Summit Therapeutics Inc. does not currently pay a dividend.
How profitable is SMMT?
In FY2025, Summit Therapeutics Inc. had a return on equity of -163.9%.
What is the analyst price target for SMMT?
The average Wall-Street price target for Summit Therapeutics Inc. is $28.39, about 88.0% above the recent price, from 13 analysts (consensus: buy).
Is SMMT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Summit Therapeutics Inc.: a Piotroski F-score of 1/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.